Qiagen (NYSE:QGEN) Shares Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC raised its holdings in Qiagen (NYSE:QGEN) by 24.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,506 shares of the company’s stock after purchasing an additional 3,878 shares during the quarter. Sanctuary Advisors LLC’s holdings in Qiagen were worth $834,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in QGEN. GAMMA Investing LLC raised its position in Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Qiagen during the second quarter worth about $27,000. Massmutual Trust Co. FSB ADV raised its holdings in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares in the last quarter. Headlands Technologies LLC lifted its position in Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares during the period. Finally, CWM LLC boosted its holdings in Qiagen by 11.5% in the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after purchasing an additional 287 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on QGEN shares. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Jefferies Financial Group restated a “buy” rating and set a $54.00 target price (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.88.

Qiagen Price Performance

Shares of NYSE QGEN opened at $44.82 on Tuesday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The company’s 50-day moving average price is $43.33 and its 200 day moving average price is $43.76. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The stock has a market cap of $10.23 billion, a price-to-earnings ratio of 114.92, a PEG ratio of 3.52 and a beta of 0.35.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.